LY4050784 + pembrolizumab + pemetrexed + carboplatin

LY4050784 + pembrolizumab + pemetrexed + carboplatin is an investigational combination regimen studied in patients with advanced or metastatic solid tumors, especially non-small cell lung cancer (NSCLC) with SMARCA4 (BRG1) alterations. - **LY4050784** is a selective, oral inhibitor of SMARCA2 (BRM), designed to target tumors with loss of SMARCA4 function. - **Pembrolizumab** is a monoclonal antibody immune checkpoint inhibitor targeting PD-1, blocking its interaction with PD-L1 and PD-L2, enhancing the immune response against tumor cells. - **Pemetrexed** is a small molecule antifolate chemotherapeutic that inhibits enzymes involved in folate metabolism and DNA synthesis (notably thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase). - **Carboplatin** is a platinum-based chemotherapeutic causing DNA crosslinking and cell death. The combination is being evaluated for safety, tolerability, and preliminary efficacy in ongoing phase 1 clinical trials, especially in individuals with BRG1/SMARCA4-deficient tumors or advanced/metastatic solid tumors that have progressed after standard treatments[1][3][7][9].

Brand names

none for carboplatin or LY4050784